RIXADONE (Alphapharm Pty Ltd)
Product name
RIXADONE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
124 working days (255)
Active ingredients
risperidone
Registration type
EOI
Indication
Generic medicine
RIXADONE is now also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the Alzheimer type.